DepoTech Receives Notice of Allowance for Drug Delivery Patent.SAN DIEGO--(BW HealthWire)--Nov. 19, 1997--DepoTech(R) Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :DEPO DEPO Delegated Episcopal Pastoral Oversight DEPO Devils Postpile National Monument (US National Park Service) DEPO Defence Export Promotion Organization (Pakistan) DEPO Double Even Pass Odd ) today announced that it has received notice of allowance from the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property for a patent covering a novel method of prolonging drug release from liposomes Liposomes Aqueous compartments enclosed by lipid bilayer membranes; liposomes are also known as lipid vesicles. Phospholipid molecules consist of an elongated nonpolar (hydrophobic) structure with a polar (hydrophilic) structure at one end. including the company's proprietary DepoFoam(TM) sustained-release drug delivery system. DepoFoam technology consists of microscopic, spherical particles that can be used to encapsulate en·cap·su·late v. 1. To form a capsule or sheath around. 2. To become encapsulated. en·cap a wide variety of drugs. DepoFoam formulations is designed to release drugs over an extended period of time ranging from days to several weeks. The patent, entitled "Cyclodextrin Liposomes Encapsulating Pharmacologic Compounds and Methods for Their Use," describes liposomal compositions that contain drug complexes with cyclodextrin molecules that slow the rate of release of the drug. The patent also describes a method for increasing the effective half-life effective half-life n. See half-life. effective half-life, n See life, radioactive. of drugs using these novel compositions and a method of treating diseases using the liposomes containing the drug-cyclodextrin complexes. "This new patent illustrates the versatility of DepoTech's technology and may open up new applications for our DepoFoam drug delivery platform," said John P. Longenecker, Ph.D., DepoTech's senior vice president and chief operations officer. DepoTech is a drug delivery company dedicated to the development and manufacture of innovative sustained-release therapeutic products based on DepoFoam. Products are being developed to satisfy medical needs in cancer, infectious diseases infectious diseases: see communicable diseases. , pain management and other fields. The company has filed a New Drug Application with the U.S. Food and Drug Administration for its lead product, DepoCyt(TM), an anti-cancer drug for the treatment of neoplastic meningitis The infiltration of the subarachnoid space with cancer cells. The cancer cells can be metastatic or from a primary brain tumor like medulloblastoma. . This press release may contain forward-looking statements regarding DepoTech and its clinical programs. Actual results could differ materially from those described in this press release as a result of a number of factors, including, but not limited to the following: There can be no assurance that any product in the DepoTech product pipeline will be successfully developed or manufactured, or that final results of human clinical trials will be supportive of regulatory approvals required to market products, or that final regulatory approval will be received in a timely manner, if at all, or that patient and physician acceptance of these products will be achieved, or that patents owned or licensed by the company would be held valid by a court of competent jurisdiction, or that third parties will not assert infringement claims against the company in the future. The company undertakes no obligation to revise or update any such forward-looking statements to reflect events or circumstances after the date of this release. Additional written materials and recent releases regarding DepoTech are available on the World Wide Web at http://www.depotech.com . -0- Note to Editors: DepoCyt is a trademark of DepoTech Corporation and Chiron Corporation Chiron Corporation was a multinational biotechnology firm based in Emeryville, California that was acquired by Novartis International AG on April 20 2006. It had offices and facilities in eighteen countries on five continents. . DepoFoam is a trademark of DepoTech Corporation. CONTACT: DepoTech Corp. Edward L. Erickson, 619/625-2424 or StratiPoint Group Mike Jackman, 415/388-3216 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion